-
Mashup Score: 5The evolving pattern of the monoclonal protein improves the IMWG 2/20/20 classification for patients with smoldering multiple myeloma - 11 day(s) ago
The 2/20/20 International Myeloma Working Group (IMWG) score is the most employed risk score in clinical practice to evaluate the risk of progression from smoldering multiple myeloma (SMM) to symptom…
Source: onlinelibrary.wiley.comCategories: General Medicine News, Hematologists1Tweet
-
Mashup Score: 4
The proportion of non-transplant-eligible (NTE) newly diagnosed multiple myeloma (NDMM) patients excluded from clinical trials (CTs) and their prognosis is unknown. CT results may not be generalizable to real-world practice due to strict recruitment criteria. We analyzed causes of NTE-NDMM patient exclusion form CTs and their outcomes. A total of 211 NTE-NDMM patients were included. They were divided into three periods: 2003–2007, 2008–2012, and 2013–2017. Overall, 50% received non-trial treatment (NCT), while 50% participated in a CT (20% control group (CG) and 30% experimental group (EG)). Main causes for exclusion from CTs were comorbidities, ECOG > 2, and renal insufficiency. In the first two periods, the CR rate was similar regardless of treatment type, but in the last period, the EG group showed improved CR. Median PFS was similar in the first two periods, with a benefit seen only in the EG in the last period. The median OS was significantly longer in CT-included patients compare
Source: www.mdpi.comCategories: General Medicine News, Hematologists1Tweet
-
Mashup Score: 7Paper: Evolving Pattern Improves the IMWG 2/20/20 Classification for Patients with Smoldering Multiple Myeloma - 1 year(s) ago
Oral and Poster Abstracts 652. Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster I Research, epidemiology, Clinical Research, Plasma Cell Disorders, Diseases, real-world evidence, Lymphoid Malignancies, survivorship Luis Gerardo Rodríguez-Lobato, MD, PhD*, Anna de Daniel i Bisbe, MD*, Natalia Tovar, MD, PhD*, Raquel…
Source: ash.confex.comCategories: Hematologists1, Latest HeadlinesTweet
-
Mashup Score: 7Paper: Bicistronic CAR T Cell Against CD229 and BCMA Effectively Controls Multiple Myeloma - 1 year(s) ago
Oral and Poster Abstracts 703. Cellular Immunotherapies: Basic and Translational: Poster III Research, Biological therapies, Translational Research, Plasma Cell Disorders, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Diseases, Therapies, Lymphoid Malignancies Luis Gerardo Rodríguez-Lobato, MD, PhD1*, Oriol Cardus, MSc1*, Joan Mañe-Pujol, MSc1*, Anthony M…
Source: ash.confex.comCategories: Hematologists1, Latest HeadlinesTweet
-
Mashup Score: 2
L’IDIBAPS impulsa diversos programes per facilitar que professionals assistencials compaginin l’atenció als malalts amb la recerca biomèdica o gaudeixin de períodes de dedicació intensiva a la investigació.
Source: Clínic BarcelonaCategories: Hematologists1, Latest HeadlinesTweet
Read more 👇: https://t.co/PViVHvCQAq @Hemasphere_EHA